{
    "nctId": "NCT04202328",
    "briefTitle": "T-DM1 in HER2-positive Metastatic/Relapsed Breast Cancer",
    "officialTitle": "A Retrospective Study for Evaluation of Real-world Efficacy and Safety of T-DM1 in HER2-positive Locally-advanced Unresectable or Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1000,
    "primaryOutcomeMeasure": "Progression free Survival, PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age \u226519 years at the time of study registration\n2. Participants must have histologically confirmed HER2-positive breast cancer\n3. Locally advanced unresectable or metastatic patients\n4. Patients who have received T-DM1 therapy between Aug 2017 and December 2018 under the Korea National Health Insurance System\n\nExclusion Criteria:\n\n\u2022 Patients who have received T-DM1 therapy outside of the Korea National Health Insurance System",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}